Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Direct Payment

$100,000.00

Determining the role of BTNL2 in mucosal and systemic immune responses.

EF 2010-11

Résumé
The intestinal immune system has the difficult task in deciding what poses a threat to the body, and how to appropriately respond to it. This is due to the continual exposure to non-harmful bacteria that reside in the intestine which should be ignored versus infectious agents that need to be killed. Strict control of when to respond to a threat is achieved by several different mechanisms to prevent responses to our own body and non-threatening substances. Loss of this ability to distinguish good from bad can result in a number of conditions including food allergy, and inflammatory bowel disease (IBD). At present, genetic changes have been found in patients that suffer from IBD in a number of genes that may help to prevent reactions to harmless substances. One such gene, called BTNL2 can reduce isolated immune cell functions in a test tube, but its function, and location in the body is currently unknown. In our studies, we will first identify what immune cells have BTNL2. This is to be done in cells isolated from both healthy control mice and those with an experimentally induced IBD. So far, our early research has found that in healthy mice, BTLN2 is expressed by immune cells not just within the intestine. These cells called dendritic cells monitor the tissues they reside in and direct immune responses to threats they detect. As these dendritic cells are very important in immune responses throughout the body, we will also determine what the role of BTNL2 is in other organ systems and models of disease including vaccination and diabetes. This research aims to fill this gap our in knowledge, and to determine if BTNL2 could serve as a basis for treatments of diseases including IBD in humans.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
214186
Name
Reardon Colin
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Determining the role of BTNL2 in mucosal and systemic immune responses.
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Colitis; Dendritic Cells; Diabetes; Flow Cytometry; Immunity; Knockout Mice; Mucosal Immunology; Nucleofection; Qrt-Pcr; Sirna
Abstract
The intestinal immune system has the difficult task in deciding what poses a threat to the body, and how to appropriately respond to it. This is due to the continual exposure to non-harmful bacteria that reside in the intestine which should be ignored versus infectious agents that need to be killed. Strict control of when to respond to a threat is achieved by several different mechanisms to prevent responses to our own body and non-threatening substances. Loss of this ability to distinguish good from bad can result in a number of conditions including food allergy, and inflammatory bowel disease (IBD). At present, genetic changes have been found in patients that suffer from IBD in a number of genes that may help to prevent reactions to harmless substances. One such gene, called BTNL2 can reduce isolated immune cell functions in a test tube, but its function, and location in the body is currently unknown. In our studies, we will first identify what immune cells have BTNL2. This is to be done in cells isolated from both healthy control mice and those with an experimentally induced IBD. So far, our early research has found that in healthy mice, BTLN2 is expressed by immune cells not just within the intestine. These cells called dendritic cells monitor the tissues they reside in and direct immune responses to threats they detect. As these dendritic cells are very important in immune responses throughout the body, we will also determine what the role of BTNL2 is in other organ systems and models of disease including vaccination and diabetes. This research aims to fill this gap our in knowledge, and to determine if BTNL2 could serve as a basis for treatments of diseases including IBD in humans.
Competitiondate
201010
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Reardon, Colin
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $100,000~ $0~